AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
AbbVie (ABBV) reported positive Phase 3 trial results for etentamig, showing a 74% objective response rate and 60% risk reduction in disease progression in relapsed/refractory multiple myeloma patients. The study met primary endpoints of ORR and PFS, with manageable safety profile. Full results will be presented at the 23rd International Myeloma Society Annual Meeting in 2026.
How this was made
The 30-second read
Why it matters
The data could accelerate AbbVie's market share in relapsed/refractory multiple myeloma and support higher valuation multiples for its oncology segment.
Market read
First‑time disclosure of pivotal trial results; likely to move ABBV stock and influence the broader oncology biotech space.
What to watch
Regulatory pathway timing and reimbursement landscape could moderate the upside despite strong data.
Background
AbbVie is expanding its oncology portfolio with BCMA‑directed therapies; etentamig is a bispecific T‑cell engager.
Ticker impact
AbbVie (ABBV) announced positive Phase 3 CERVINO trial results for etentamig, showing 74% ORR and 60% PFS risk reduction versus standard therapies.
Short-term upside pressure on ABBV as investors price in a new late‑stage asset; potential 5‑10% rally if data is confirmed.
Phase 3 data is material, first disclosure, and shows statistically significant efficacy with manageable safety, a catalyst that can move the stock.
Market effects
Strengthens the BCMA‑targeted bispecific antibody segment and may pressure competitors' pipelines.
Positive for US biotech sector; may lift related oncology stocks.
Adds to global multiple myeloma treatment landscape, potentially influencing European and Asian biotech valuations.
Counterpoint
If safety concerns or manufacturing challenges emerge, the hype could fade and the stock may underperform.
Key entities
- companyAbbVie
US‑listed biopharma developing etentamig.
- drugetentamig
Investigational BCMA × CD3 bispecific T‑cell engager.
%252FAbbvie%252520Inc%252520HQ%252520photo-by%252520vzphotos%252520via%252520iStock.jpg&w=3840&q=75)
